Overview

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

Status:
Completed
Trial end date:
2017-06-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetic parameters and safety of topical MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use conditions.
Phase:
Phase 2
Details
Lead Sponsor:
Medimetriks Pharmaceuticals, Inc